tbuckley/cabot-search huggingface dataset:
Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe
Authors: Hannah Fraser, Natasha K. Martin, Henrikki Brummer-Korvenkontio, Patrizia Carrieri, Olav Dalgard, John Dillon, David Goldberg, Sharon Hutchinson, Marie Jauffret-Roustide, Martin Kåberg, Amy A. Matser, Mojca Matičič, Havard Midgard, Viktor Mravcik, Anne Øvrehus, Maria Prins, Jens Reimer, Geert Robaeys, Bernd Schulte, Daniela K. van Santen, Ruth Zimmermann, Peter Vickerman, Matthew Hickman
Journal: Journal of Hepatology (2018)

Highlights•Chronic HCV prevalence and treatment rates among PWID vary widely across Europe.•HCV treatment scale-up is required in most sites to reduce HCV transmission.•Increasing OST/NSP coverage enhances HCV treatment prevention benefit.Graphical abstractAbstractBackground & AimsPrevention of hepatitis C virus (HCV) transmission among people who inject drugs (PWID) is critical for eliminating HCV in Europe. We estimated the impact of current and scaled-up HCV treatment with and without scaling up opioid substitution therapy (OST) and needle and syringe programmes (NSPs) across Europe over the next 10 years.MethodsWe collected data on PWID HCV treatment rates, PWID prevalence, HCV prevalence, OST, and NSP coverage from 11 European settings. We parameterised an HCV transmission model to setting-specific data that project chronic HCV prevalence and incidence among PWID.ResultsAt baseline, chronic HCV prevalence varied from <25% (Slovenia/Czech Republic) to >55% (Finland/Sweden), and <2% (Amsterdam/Hamburg/Norway/Denmark/Sweden) to 5% (Slovenia/Czech Republic) of chronically infected PWID were treated annually. The current treatment rates using new direct-acting antivirals (DAAs) may achieve observable reductions in chronic prevalence (38–63%) in 10 years in Czech Republic, Slovenia, and Amsterdam. Doubling the HCV treatment rates will reduce prevalence in other sites (12–24%; Belgium/Denmark/Hamburg/Norway/Scotland), but is unlikely to reduce prevalence in Sweden and Finland. Scaling-up OST and NSP to 80% coverage with current treatment rates using DAAs could achieve observable reductions in HCV prevalence (18–79%) in all sites. Using DAAs, Slovenia and Amsterdam are projected to reduce incidence to 2 per 100 person years or less in 10 years. Moderate to substantial increases in the current treatment rates are required to achieve the same impact elsewhere, from 1.4 to 3 times (Czech Republic and France), 5–17 times (France, Scotland, Hamburg, Norway, Denmark, Belgium, and Sweden), to 200 times (Finland). Scaling-up OST and NSP coverage to 80% in all sites reduces treatment scale-up needed by 20–80%.ConclusionsThe scale-up of HCV treatment and other interventions is needed in most settings to minimise HCV transmission among PWID in Europe.Lay summaryMeasuring the amount of HCV in the population of PWID is uncertain. To reduce HCV infection to minimal levels in Europe will require scale-up of both HCV treatment and other interventions that reduce injecting risk (especially OST and provision of sterile injecting equipment).
Abstract 17413: Plasma Lipidomic Profiles in Two Large Independent Cohorts Improve Upon Conventional Risk Factors to Predict Cardiovascular Events
Authors: Piyushkumar A Mundra, Christopher K Barlow, Paul J Nestel, Elizabeth H Barnes, Adrienne Kirby, Peter Thompson, David R Sullivan, Zahir H Alshehry, Natalie A Mellett, Kevin Huynh, Malcolm J McConville, Sophia Zoungas, Graham S Hillis, John Chalmers, Mark Woodward, Gerard Wong, Bronwyn A Kingwell, John Simes, Andrew M Tonkin, Peter J Meikle
Journal: Circulation (2016)

Introduction: Secondary prevention in cardiovascular disease (CVD) consumes considerable resources due in part to our limited ability to stratify risk in this group. We used lipidomics to evaluate ...
Transsynaptic Mapping of Second-Order Taste Neurons in Flies by trans-Tango
Authors: Mustafa Talay, Ethan B. Richman, Nathaniel J. Snell, Griffin G. Hartmann, John D. Fisher, Altar Sorkaç, Juan F. Santoyo, Cambria Chou-Freed, Nived Nair, Mark Johnson, John R. Szymanski, Gilad Barnea
Journal: Neuron (2017)
Acupuncture for Infertility in Polycystic Ovary Syndrome—Reply
Authors: Xiao-Ke Wu, Elisabet Stener-Victorin, Heping Zhang
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Musculoskeletal injury profiles in professional Women’s Tennis Association players
Authors: Jodie G Dakic, Belinda Smith, Cameron M Gosling, Luke G Perraton
Journal: British Journal of Sports Medicine (2017)

The physical demands of professional tennis combined with high training/match loads can contribute to musculoskeletal injury. The objectives of this study were to (1) describe the type, location and severity of injuries sustained during a 12-month tennis season in a cohort of professional female tennis players on the Women's Tennis Association (WTA) tour and (2) prospectively investigate associations between training/match loads and injury.52 WTA players competing at the Australian Open (2015) consented to participate. Injuries reported to WTA medical staff were classified using tennis-specific guidelines. Individual match exposure data were collected for all matches played at international level in 2015 and expressed per 1000 hours of WTA competition matchplay (MP) and 1000 match exposures (MEs). Variables associated with the number of injuries in the season and loss of time from competition were identified with regression analysis.The injury incidence rate (IR) was 56.6 (95% CI: 49.5 to 64.6) per 1000 hours of MP or 62.7 (95% CI: 54.8 to 71.6) per 1000 MEs, although the IR of injuries resulting in loss of time from competition was lower (12.8 per 1000 hours of MP, 92 injuries/100 players). Lower limb (51%) and muscle/tendon (50%) injuries were the most common site and type of injury. Common specific injury site subcategories were the thigh, shoulder/clavicle, ankle and knee in order of frequency. Various measures of match load were significantly associated with injury.This study prospectively analysed injury profiles, including severity across an entire season of professional tennis, and investigated the relationship between training/match loads and injury. These data may help medical professionals develop injury risk identification and prevention programmes.
Daytime variation of perioperative myocardial injury in cardiac surgery and its prevention by Rev-Erbα antagonism: a single-centre propensity-matched cohort study and a randomised study
Authors: David Montaigne, Xavier Marechal, Thomas Modine, Augustin Coisne, Stéphanie Mouton, Georges Fayad, Sandro Ninni, Cédric Klein, Staniel Ortmans, Claire Seunes, Charlotte Potelle, Alexandre Berthier, Celine Gheeraert, Catherine Piveteau, Rebecca Deprez, Jérome Eeckhoute, Hélène Duez, Dominique Lacroix, Benoit Deprez, Bruno Jegou, Mohamed Koussa, Jean-Louis Edme, Philippe Lefebvre, Bart Staels
Journal: The Lancet (2017)
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study
Authors: Margaret K. Callahan, Harriet Kluger, Michael A. Postow, Neil H. Segal, Alexander Lesokhin, Michael B. Atkins, John M. Kirkwood, Suba Krishnan, Rafia Bhore, Christine Horak, Jedd D. Wolchok, Mario Sznol
Journal: Journal of Clinical Oncology (2017)

Purpose The clinical activity observed in a phase I dose-escalation study of concurrent therapy with nivolumab (NIVO) and ipilimumab (IPI) in patients with previously treated or untreated advanced melanoma led to subsequent clinical development, including randomized trials. Here, we report long-term follow-up data from study CA209-004, including 3-year overall survival (OS). Patients and Methods Concurrent cohorts 1, 2, 2a, and 3 received escalating doses of NIVO plus IPI once every 3 weeks for four doses, followed by NIVO once every 3 weeks for four doses, then NIVO plus IPI once every 12 weeks for eight doses. An expansion cohort (cohort 8) received concurrent NIVO 1 mg/kg plus IPI 3 mg/kg once every 3 weeks for four doses, followed by NIVO 3 mg/kg once every 2 weeks, which is the dose and schedule used in phase II and III studies and now approved for patients with unresectable or metastatic melanoma. Results Among all concurrent cohorts (N = 94) at a follow-up of 30.3 to 55.0 months, the 3-year OS rate was 63% and median OS had not been reached. Objective response rate by modified WHO criteria was 42%, and median duration of response was 22.3 months. Incidence of grade 3 and 4 treatment-related adverse events was 59%. The most common grade 3 and 4 treatment-related adverse events were increases in lipase (15%), alanine aminotransferase (12%), and aspartate aminotransferase (11%). One treatment-related death (1.1%) occurred in a patient who had multiorgan failure 70 days after the last dose of NIVO plus IPI. Conclusion This is the longest follow-up for NIVO plus IPI combination therapy in patients with advanced melanoma. The 3-year OS rate of 63% is the highest observed for this patient population and provides additional evidence for the durable clinical activity of immune checkpoint inhibitors in the treatment of advanced melanoma.
A Strange Digital Tumor
Authors: Greta Gourier, Anne-Marie Roguedas-Contios, Laurent Misery
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
TCT-121 Bioprosthetic aortic valve leaflet thrombosis detected by multidetector computed tomography is associated with adverse cerebrovascular events: a meta-analysis of observational studies
Authors: Hashrul Rashid, Abdul Rahman Ihdayhid, Liam McCormick, Nitesh Nerlekar, James Cameron, Arthur Nasis, Robert Gooley, Adam Brown
Journal: Journal of the American College of Cardiology (2017)
TCT-19 Mid- and long-term outcome of the EXPLORE trial, a Global, Randomized, Prospective, Multicenter Trial Investigating the Impact of Recanalization of a Chronic Total Occlusion in Patients after Primary Percutaneous Coronary Intervention for Acute ST-Elevation Myocardial Infarction
Authors: Joelle Elias, Ivo M. van Dongen, Peep Laanmets, Erlend Eriksen, Martijn Meuwissen, Matthijs Bax, Dan Ioanes, Maarten Suttorp, Bradley Strauss, Emanuele Barbato, Koen Marques, Bimmer E.P.M. Claessen, Alexander Hirsch, Rene van der Schaaf, Jan Tijssen, Loes P. Hoebers, Jose P.S. Henriques
Journal: Journal of the American College of Cardiology (2017)
Estimating the fitness cost and benefit of cefixime resistance in Neisseria gonorrhoeae to inform prescription policy: A modelling study
Authors: Lilith K. Whittles, Peter J. White, Xavier Didelot
Journal: PLoS Medicine (2017)

Background Gonorrhoea is one of the most common bacterial sexually transmitted infections in England. Over 41,000 cases were recorded in 2015, more than half of which occurred in men who have sex with men (MSM). As the bacterium has developed resistance to each first-line antibiotic in turn, we need an improved understanding of fitness benefits and costs of antibiotic resistance to inform control policy and planning. Cefixime was recommended as a single-dose treatment for gonorrhoea from 2005 to 2010, during which time resistance increased, and subsequently declined. Methods and findings We developed a stochastic compartmental model representing the natural history and transmission of cefixime-sensitive and cefixime-resistant strains of Neisseria gonorrhoeae in MSM in England, which was applied to data on diagnoses and prescriptions between 2008 and 2015. We estimated that asymptomatic carriers play a crucial role in overall transmission dynamics, with 37% (95% credible interval CrI 24%–52%) of infections remaining asymptomatic and untreated, accounting for 89% (95% CrI 82%–93%) of onward transmission. The fitness cost of cefixime resistance in the absence of cefixime usage was estimated to be such that the number of secondary infections caused by resistant strains is only about half as much as for the susceptible strains, which is insufficient to maintain persistence. However, we estimated that treatment of cefixime-resistant strains with cefixime was unsuccessful in 83% (95% CrI 53%–99%) of cases, representing a fitness benefit of resistance. This benefit was large enough to counterbalance the fitness cost when 31% (95% CrI 26%–36%) of cases were treated with cefixime, and when more than 55% (95% CrI 44%–66%) of cases were treated with cefixime, the resistant strain had a net fitness advantage over the susceptible strain. Limitations include sparse data leading to large intervals on key model parameters and necessary assumptions in the modelling of a complex epidemiological process. Conclusions Our study provides, to our knowledge, the first estimates of the fitness cost and benefit associated with resistance of the gonococcus to a clinically relevant antibiotic. Our findings have important implications for antibiotic stewardship and public health policies and, in particular, suggest that a previously abandoned antibiotic could be used again to treat a minority of gonorrhoea cases without raising resistance levels.
Pro-COL11A1: A biomarker to predict malignant relapse of breast intraductal papillomas.
Authors: Javier Freire, Lucia Garcia-Berbel, Saioa Dominguez-Hormaetxe, Saray Pereda, Ana De Juan, Angela Hens, Ana Fernandez Montes, Laureano Simon, Javier Gomez-Roman
Journal: Journal of Clinical Oncology (2013)

540 Background: Breast cancer is currently the most frequent tumor among women. Despite the huge progress achieved in its early diagnosis, there are still many unsolved clinical issues, being the diagnosis, prognosis and treatment of papillary diseases (and specifically intraductal papilloma), one of the highest challenges. Because of its unpredictable clinical behavior, treatment of intraductal papilloma has generated a great controversy. Even though considered as a benign lesion, it presents high rate of malignant recurrence. This is the reason why there are clinicians supporting a complete excision of the papillary lesion, while others support an only expectant follow up. Previous results of our group have suggested that pro-Collagen 11 alpha 1 (pro-COL11A1) expression in cancer associated fibroblasts (CAFs) correlates with an infiltrating phenotype in breast lesions. We have analyzed the correlation between the differential expression of pro-COL11A1 in intraductal papilloma and their risk of malignant recurrence. Methods: Immunohistochemistry of pro-COL11A1 (clone 1E8.33, ONCOMATRIX, Bilbao, SPAIN) was performed in formalin fixed, paraffin embedded Core Needle Biopsy samples of 51 patients with intraductal papilloma. All patients had a minimum follow-up of 5 years. Results: Twenty-three out of 51 cases showed positive staining for COL11A1. Nine patients out of the positive cases relapsed as infiltrating carcinoma, two as intraductal papilloma and the rest had not recurred after five years of follow up. Only one case out of the 28 negative cases relapsed as invasive carcinoma. There were significant differences (p=0.0013) when comparing staining of individuals with malignant recurrence versus non recurrence and benign relapse patients, with a sensitivity of 90% and specificity of 66%. Conclusions: These data suggest that COL11A1 expression in CAFs is a highly sensitive biomarker to predict malignant relapse of intraductal papilloma. The low specificity might be biased by the complete excision of this lesion as the routine treatment or by a short follow-up of the patients.
Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma
Authors: Alex F Herrera, Nancy L Bartlett, Radhakrishnan Ramchandren, Julie M Vose, Alison J Moskowitz, Tatyana A Feldman, Ann S LaCasce, Stephen M Ansell, Craig H. Moskowitz, Keenan Fenton, Kazunobu Kato, Abraham Fong, Ranjana H Advani
Journal: Blood (2016)
In vivo induction of tumor-specific CTL against CEA-antigens and MAGE-3 antigens expressed on human lung adenocarcinoma by using CEA gene therapy
Authors: Masaji Okada, Takao Tanaka, Yoko Kita, Sachiko Kuwayama, Yumiko Muraki, Noriko Kanamaru, Satomi Hashimoto, Hiroko Takai, Chika Okada, Yukari Fukunaga, Yayoi Sakaguchi, Izumi Furukawa, Kyoko Yamada, Satoru Yamamoto, Akihide Matsumura, Keiji Iuchi, Masaaki Kawahara, Sakatani Mitsunori
Journal: Cancer Research (2004)

5140   In previous study we showed synergistic effect of IL-6 related genes (IL-6 gene, IL-6 receptor gene and gp130 gene) on the induction of CTL against human cancer cells using SCID-PBL/hu experimental model. In this model IL-6 related genes were administered in vivo using adenovirus vector into SCID-PBL/hu mice bearing human cancers, and induced CTL activity against human tumor cells (lung cancer, stomach cancer, colon cancer) and significant prolonged survival of mice was observed. IL-6 related genes (IL-6 gene+IL-6 receptor(R) gene+gp130 gene) were injected intraperitoneally(i-p) into SCID-PBL/hu mice in vivo by using this experimental model (SCID mice given PBL from lung cancer patient and autologous lung cancer cells). Furthermore, the in vivo generation of human CTL against MAGE-3 peptide (9 amino acids) when SCID-PBL/hu were treated with the MAGE-3 peptide capable of binding HLA-A24 and IL-6 related genes. The human CTL activity generated in vivo from spleen cells, mesenteric lymph node cells and peritoneal exudate cells (PEC) in these SCID-PBL/hu mice was exerted against the human target cells expressed HLA-A24, but not HLA-A2. Furthermore, the in vivo human CTL against CEA antigen were generated when SCID-PBL/hu were treated with CEA genes by using adenovirus vector. The human CD8 positive CTL activity generated in vivo from spleen cells in these SCID-PBL/hu mice was exerted against the human CEA- positive tumor cells expressed the same HLA- A24 as the donor of human PBL possessed. Therefore, it was demonstrated that these human CTL generated in vivo in SCID-PBL/hu mice were antigen specific and HLA-restricted. To our knowledge, it is quite difficult to generate the in vivo CTL against tumor associate antigens in human treated with several kinds of cancer vaccines (tumor associated antigens vaccines). MAGE-3 antigens and CEA antigens were expressed on 30∼40% of human lung cancers and almost of lung adenocarcinoma in Japan. Therefore, the SCID-PBL/hu model using CEA gene or peptides of tumor associated antigens might provide a powerful weapon for developing new cancer vaccines against human lung cancers. (Co-worker: Kazuto Takesako: Takara-shuzo Central Institute, Izumu Saito: Tokyo University) (Grant sponsor: Ministry of Health Labor and Welfare, Japan (Second Term Comprehensive 10-year Strategy for Cancer Control: Grant number: H-14gan-033)
Response to Comment on Lachin et al. Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. Diabetes Care 2017;40:777–783
Authors: John M. Lachin, Ionut Bebu, Richard M. Bergenstal, Rodica Pop-Busui, F. John Service, Bernard Zinman, David M. Nathan
Journal: Diabetes Care (2017)

Fleischer et al. (1) contend that discrete blood glucose measurements such as those in the 7-point profile in the Diabetes Control and Complications Trial (DCCT) fail to provide an accurate measure of mean amplitude of glycemic excursions (MAGE). However, this is not borne out by their post hoc analysis of the two studies cited (their refs. 2 and 3) related to autonomic modulation. It is unclear which of the many SMBG measurements performed each day (ref. 2) were selected as the seven values used to calculate MAGE. The design of the study made it unlikely that they were carefully timed premeal and 90 min postmeal. The use of three (premeal) and bedtime SMBG results in ref. 3 precludes a reliable calculation of MAGE.

The broader issue of whether discrete blood glucose values can provide as …
TCT-171 Optical Coherence Tomography evaluation of the Absorb bioresorbable scaffold performance for overlap versus non-overlap segments in patients with coronary chronic total occlusion: insights from the GHOST-CTO registry
Authors: Gabriel Tensol Rodrigues Pereira, Alessio La Manna, Eligio Miccichè, Guido D'Agosta, Armando Vergara-Martel, Giacomo Gravina, Bruno Ramos Nascimento, Guilherme F. Attizzani, Davide Capodanno, Corrado Tamburino
Journal: Journal of the American College of Cardiology (2017)
Prospective study of body mass index and risk of sarcoidosis in US women
Authors: Orianne Dumas, Krislyn M. Boggs, Yvette C. Cozier, Meir J. Stampfer, Carlos A. Camargo
Journal: European Respiratory Journal (2017)

Sarcoidosis is a systemic inflammatory disorder, characterised by the formation of immune granulomas that can occur in various organs, but typically affects the lungs [1]. Although sarcoidosis resolves spontaneously in many cases, about one-third of patients experience chronic disease associated with significant morbidity [2]. A higher BMI is prospectively associated with an increased risk of developing sarcoidosis in women <http://ow.ly/OQ6k30f7XaQ> The Nurses' Health Study II is coordinated at the Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA. We would like to thank the participants and staff of the Nurses' Health Study II for their valuable contributions.